 ROCKVILLE, Md.--BUSINESS WIRE--GlycoMimetics Nasdaq: GLYC product candidate uproleselan when added to a combination therapy of venetoclax and a hypomethylating agent HMA was shown today in an oral presentation to break chemoresistance by dramatically and significantly reducing tumor burden as detected by circulating human AML cells after three weeks of treatment, and by significantly increasing survival p 0.0009 in an animal model engrafted with AML from a patient with acquired r 